Op­ti­miz­eRx builds out pa­tient DTC mar­ket­ing with $95M ac­qui­si­tion

Last year
Deals
Pharma

BIO, PhRMA, oth­ers seek tweaks to FDA draft guid­ance on di­ver­si­ty in post­mar­ket­ing stud­ies

Last year
Pharma
FDA+

Biotech in Is­rael: Hold­ing on to busi­ness as usu­al amid un­cer­tain times

Last year
Startups
R&D

Har­mo­ny Bio­sciences' Wak­ix fails PhI­II hy­per­som­nia study; Flori­da gene ther­a­py start­up down­sizes

Last year
News Briefing

Sanofi’s eczema drug hits pri­ma­ry end­point in PhI­Ib tri­al, plans un­der­way for PhI­II in 2024

Last year
R&D

Am­gen gives first glimpse at PRMT5 in­hibitor, days af­ter Bris­tol My­ers put a $1B promise on the tar­get

Last year
R&D
Pharma

EU com­mit­tee con­firms neg­a­tive opin­ion for Amy­lyx ALS drug, re­ject­ing com­pa­ny ap­peal

Last year
FDA+

Pfiz­er lands FDA ap­proval for $6.7B ul­cer­a­tive col­i­tis drug, tak­ing on an­ti­bod­ies as an oral al­ter­na­tive

Last year
R&D
Pharma

Cas­sa­va re­sponds to ac­cu­sa­tions of 'sci­en­tif­ic mis­con­duct,' re­it­er­ates sup­port of da­ta be­hind con­tro­ver­sial ...

Last year
R&D

Po­sei­da pro­motes cell ther­a­py pres­i­dent to CEO; Af­ter IPO, Neumo­ra ap­points R&D chief

Last year
Peer Review

San­thera gears up for EU launch of va­morolone in Duchenne af­ter pos­i­tive CHMP opin­ion

Last year
Pharma

Most de­tailed hu­man brain map yet is ‘lay­ing the foun­da­tion for find­ing fu­ture cures’

Last year
R&D
In Focus

Flag­ship Pi­o­neer­ing re­casts its cor­po­rate brand with ‘Big­ger Leaps’ tagline and am­bi­tion

Last year
Pharma
Marketing

More than 'just a rash': In­cyte taps Mandy Moore in atopic der­mati­tis cam­paign

Last year
Pharma
Marketing

Qual­i­ty con­sid­er­a­tions for top­i­cal eye treat­ments: FDA pub­lish­es new draft guid­ance

Last year
Pharma
FDA+

How an earn­ings call com­ment from Al San­drock pro­pelled an ap­peals court's re­ver­sal on a Bio­gen in­vestor suit

Last year
Pharma
Law

FDA’s drug pro­mo­tion watch­dog plans study around ad­her­ence claims in phar­ma ads

Last year
Pharma
Marketing

GSK looks to au­tho­rized gener­ic ver­sion of asth­ma treat­ment as Med­ic­aid re­bate caps lift next year

Last year
Pharma
FDA+

Pfiz­er ex­pands la­bel for block­buster BRAF/MEK com­bo in­to lung can­cer

Last year
Pharma

Re­ci­pharm CEO an­tic­i­pates 2024 will be ‘as hard’ for CD­MOs, strat­e­gy will be key for en­durance

Last year
Manufacturing

Ab­b­Vie and In­cyte re­port PhI­Ib vi­tili­go da­ta on oral JAKs an­a­lysts call ‘un­dif­fer­en­ti­at­ed’

Last year
R&D

FDA lifts hold on Pep­Gen's my­oton­ic dy­s­tro­phy drug; Take­da teams with can­cer non­prof­it

Last year
News Briefing

Eli Lil­ly touts PhI­II mirik­izum­ab win in Crohn’s de­spite woes in oth­er con­di­tions

Last year
R&D

Fu­ji­film Irvine work­force cuts; Gates Foun­da­tion in­vests in Africa-made vac­cines; Sharp ac­quires BSM

Last year
Manufacturing
First page Previous page 264265266267268269270 Next page Last page
A service from the Financial Times